Method for diagnosing early and classifying stages of alzheimer's disease and determining amyloid beta accumulation in brain by using tau protein-derived phosphorylated peptide
AssigneesGwangju Institute of Science and Technology, Seoul National University R&Db Foundation, Industry-Academic Cooperation Foundation, Chosun University
InventorsZEE-YONG PARK, SE HWAN JANG, YOU RIM KIM, DAEHEE HWANG, KUNHO LEE
Life of this patent
Estimating the term…
Abstract
A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.
Claims25
A method for early diagnosis and/or stage classification of Alzheimer's disease, the method comprising:
- (a) obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample;
- and
- (b) quantifying the tau protein-derived phosphorylated peptide.
A method for determination of amyloid beta accumulation in the brain, the method comprising:
- (a) obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample;
- and
- (b) quantifying the tau protein-derived phosphorylated peptide.
A composition for early diagnosis or stage classification of Alzheimer's disease, or for determination of amyloid beta accumulation in the brain, comprising:
- a formulation adapted to detect a phosphorylation site at one or more positions selected from the group consisting of Y394;
- S396;
- (T403/S404), Y394;
- S396, S396;
- S400;
- S404, S202, S198;
- S202, S199;
- S202, S404, S400;
- S404, T231 and T181 in tau protein.
Dependencies are inferred from the claim text.